Loading
Bacteremia / Cancer · Observational Study
ClinicalTrials.gov · August 19, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a terminated observational pilot study registered to evaluate procalcitonin as a predictor of bacteremia in febrile pediatric oncology patients. No outcome data are reported in this registry record. The study enrolled only 1 participant before termination and therefore provides no evidence on which to base clinical decisions.
Observational. Cancer, Bacteremia; to 17 Years. Intervention: Procalcitonin measurement at admission, 12 hours, and 24 hours post-admission.. n = 1. 1 site: United States.
This is a terminated observational pilot study registered to evaluate procalcitonin as a predictor of bacteremia in febrile pediatric oncology patients. No outcome data are reported in this registry record. The study enrolled only 1 participant before termination and therefore provides no evidence on which to base clinical decisions.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
No clinical impact can be derived from this terminated registry record. The study completed enrollment of only 1 participant and no outcome analysis is reported, so no evidence exists to guide clinical use of procalcitonin in this population.
This is a terminated observational pilot study with only 1 enrolled participant; no results are reported in the registry record, precluding any assessment of efficacy or clinical utility.
As stated by the source record.
Quoted from the source exactly as published.
No clinical impact can be derived from this terminated registry record. The study completed enrollment of only 1 participant and no outcome analysis is reported, so no evidence exists to guide clinical use of procalcitonin in this population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT02417168). This is a study registration, not published results. Lead sponsor: CAMC Health System. Recruitment status: TERMINATED. Study type: OBSERVATIONAL. Enrollment: 1 participants (ACTUAL). Conditions: Cancer, Bacteremia. Primary outcome measures: Change in procalcitonin levels , 24 hours. Brief summary: Fevers raise the concern for serious bacterial infections in pediatric oncology patients receiving chemotherapy. The gold standard for diagnosing bacteremia (bacterial infection of the blood) is a blood culture. However, bacterial growth may not occur for 48 hours or there can be a false negative result. Thus, the biomarker, procalcitonin, has been investigated for its predictive ability to identify bacteremia earlier than blood culture. We believe that procalcitonin can assist in differentiating bacteremia from non-bacteremia infections in febrile pediatric oncology patients. A reliable predictor of bacteremia infections in pediatric oncology patients should decrease hospitalizations for fever and unnecessary antibiotic treatment. In our study we will measure procalcitonin levels in pediatric oncology patients presenting with fever. We will measure procalcitonin at the time of admission which is part of our standard of care for febrile pediatric oncology admissions. For the purpose of our study, we will additionally measure procalcitonin levels at 12 hours and at 24 hours post admission. We will examine procalcitonin levels at these three timepoints to determine if elevated procalcitonin levels predict bacteremia in pediatric oncology patients with and without neutropenia.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.